GOFUS, Jan, Petr FILA, Martin VOBORNIK, Jiri ONDRASEK, Petr NĚMEC, Jan ŠTĚRBA, Eva CERMAKOVA, Martin TUNA a Jan VOJACEK. Unicuspid Aortic Valve in Patients Undergoing the Ross Procedure. Annals of Thoracic Surgery. New York: Elsevier Science Inc., 2023, roč. 115, č. 3, s. 626-631. ISSN 0003-4975. Dostupné z: https://dx.doi.org/10.1016/j.athoracsur.2022.03.061.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Unicuspid Aortic Valve in Patients Undergoing the Ross Procedure
Autoři GOFUS, Jan (203 Česká republika), Petr FILA (203 Česká republika, garant, domácí), Martin VOBORNIK (203 Česká republika), Jiri ONDRASEK (203 Česká republika), Petr NĚMEC (203 Česká republika, domácí), Jan ŠTĚRBA (203 Česká republika, domácí), Eva CERMAKOVA (203 Česká republika), Martin TUNA (203 Česká republika) a Jan VOJACEK (203 Česká republika).
Vydání Annals of Thoracic Surgery, New York, Elsevier Science Inc. 2023, 0003-4975.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.600 v roce 2022
Kód RIV RIV/00216224:14110/23:00130667
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.athoracsur.2022.03.061
UT WoS 000944472800001
Klíčová slova anglicky Unicuspid Aortic Valve; Ross Procedure
Štítky 14110911, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 27. 4. 2023 13:31.
Anotace
BACKGROUND The prevalence and outcomes of the unicuspid aortic valve (UAV) in patients undergoing the Ross procedure have been strongly underreported in the current literature. We sought to evaluate this in comparison with bicuspid (BAV) and tricuspid valve (TAV) in our Ross cohort.METHODS This was a retrospective observational study of patients undergoing the Ross procedure at 2 dedicated centers between 2009 and 2020. Primary end points were the risks of midterm autograft reoperation and the onset of at least moderate aortic regurgitation during follow-up. The secondary end point was to compare the perioperative out-comes between the groups.RESULTS Included in the analysis were 286 patients, of those 39% with UAV, 52% with BAV, and 9% with TAV. UAV patients were operated on at the youngest age (P < .001) and more often for a combined hemodynamic aortic valve pathology (P = .02). They had the largest aortic root dimensions: annulus (P = .01), Valsalva sinuses (P = .11), sino-tubular junction (P = .001), and ascending aorta (P < .0001). The risks of reoperation (P = .86) and the onset of aortic regurgitation (P = .75) were comparable among the groups over the follow-up of 4.1 years. There was no difference in perioperative outcomes.CONCLUSIONS UAV is a separate unit characterized by a distinct hemodynamic pathology and generated aortopathy. It is not associated with a higher risk of reoperation or new onset of aortic regurgitation after the Ross procedure in the midterm postoperatively. At the current state, UAV remains acceptable for the Ross procedure.
VytisknoutZobrazeno: 10. 10. 2024 04:09